30 results about "Positron emission" patented technology

Disclosed herein are methods and apparatus for acquiring positron emission (or PET) data in the presence of ionizing radiation causing PET detector afterglow. In one variation, the method includes adjusting a coincidence trigger threshold of a PET detector during a treatment session. In one variation, the method includes adjusting a gain factor used in positron emission data acquisition (e.g., a gain factor used to multiply and / or shift an output(s) of a PET detector(s)) during a treatment session. In some variations, a method for acquiring positron emission data during a radiation treatment session includes suspending communication between a PET detector and a signal processor of a controller for a predetermined period of time after a radiation pulse is emitted by a linear accelerator.

A compound or pharmaceutically acceptable salt thereof has at least one bis-phosphonate or bisphosphonate ester group, and a positron emitting radionuclide Po. The positron emitting radionuclide Po is attached to the at least one bisphosphonate or bisphosphonate ester group. The compound may be useful in a method of diagnosis of amyloidosis, such as cardiac amyloidosis.

The invention discloses a radioactive diagnosis medicine for targeting OPN as well as a preparation method and application of the radioactive diagnosis medicine. The radioactive diagnosis medicine comprises linear polypeptide and radionuclide, wherein the linear polypeptide is composed of 20 L-type amino acids and one D-type amino acid, and the radionuclide marks the linear polypeptide through a bifunctional chelating agent; the sequence of the linear polypeptide is as shown in SEQ ID NO. 1. In vivo, radionuclides in the medicine are concentrated to an atherosclerotic vulnerable plaque part through the targeting effect of the amino acid linear polypeptide, and imaging diagnosis is carried out on the atherosclerotic vulnerable plaque by utilizing a positron emission computed tomography technology of nuclear medicine.

Disclosed are compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof. The variables of structural formula (I) are described herein. The compound of the invention can be attached to chelating groups for radionuclide binding and are therefore suitable for radioimaging and / or radiotherapy applications, for example the disclosed compounds can be radiolabeled with a positron emitter such as 18F, 68Ga or 64Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 223 Ac, a beta particle emitter such as 67Cu or 177Lu, or an Auger electron emitter (e.g. 111In, 67Ga, 99mTc, 195mPt, 125I, 123I and 161Tb) for use as a radiotherapeutic.

An image acquisition apparatus includes a measurement unit and a processing unit. The processing unit, for each coincidence event in which a first detector and a second detector perform coincidence detection of a pair of gamma-ray photons generated by an electron positron annihilation event in a positron emitting radionuclide, assuming that the gamma-ray photon arriving at one detector is a gamma-ray photon arriving without being Compton scattered in a subject, and the gamma-ray photon arriving at another detector is a gamma-ray photon arriving after being Compton scattered in the subject, determines a position at which the gamma-ray photon is Compton scattered in the subject based on a detection position and a detection time of the gamma-ray photon by each of the first detector and the second detector and a position of the positron emitting radionuclide.

Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron-emitting mannitol analogue, [18F]fluoromannitol ([18F]FMtl), are rapidly taken up by gram-positive and gram-negative bacteria such as E. coli, S. aureus, A. baumannii, S. epidermis, P. mirabilis, S. enterica, K. pneumonia, E. faecium, E. cloacae, and M. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.

A method may include determining a first region including a lesion within a first positron emission tomography and computed tomography (PET-CT) scan depicting a plurality of regions of a body. A first portion of the first PET-CT scan depicting the first region but not depicting a second region of the plurality of regions may be extracted to generate a second PET-CT scan having one or more initial dimensions. The one or more initial dimensions of the second PET-CT scan may be adjusted to one or more target dimensions by at least adding one or more voxels to the second PET-CT scan and determining a value for each of the one or more voxels added to the second PET-CT scan. A segmentation model may be trained based on a training data set including the second PET-CT scan adjusted to the one or more target dimensions.

The present invention relates to compounds for imaging TAU protein aggregates, in particular to novel compounds of formula (II) which can be used for selective Tau detection in disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies by positron emission tomography (PET) imaging.

Systems, methods, and devices provide data correction for positron emission tomography (PET) examinations using an external, supplemental radioactive source. The supplemental radioactive source is formed of a uniformly distributed radionuclide. The uniformly distributed radionuclide is positioned in a support structure which is positioned into an inner bore of a PET scanner and secured in place by a friction fit, or directly integrated into the PET system. A transmission source control system moves the one or more 2024 / 059537 transmission sources into the support structure for performing the PET examination (e.g., using a hydraulic system). The transmission source control system also retracts the one or more transmission sources back into a source storage device upon completing the PET examination. Various data correction algorithms use the first PET signal data, originating from a radiotracer injected in the patient, and second PET signal data, originating from the uniformly distributed radionuclide.

The utility model relates to a positron emission tomography scanner, which belongs to the technical field of positron emission tomography scanners and comprises a scanner body, a mounting seat arranged outside the scanner body, a base arranged on the lower surface of the mounting seat, a supporting plate fixedly connected to the top of the base and a controller fixedly arranged outside the supporting plate. A rotating mechanism is arranged outside the mounting seat, a moving mechanism is arranged on the upper surface of the base, and the rotating mechanism comprises a gear ring rotationally mounted outside the mounting seat, a gear connected to the outside of the gear ring in a meshed mode, a driving motor fixedly mounted on the back of the mounting seat and a limiting assembly arranged on the back of the gear ring. According to the positron emission tomography scanner, the controller starts the driving motor to work to drive the gear to rotate, so that the gear rotates to be meshed with the gear ring, annular driving of the scanner body is achieved, all-directional scanning of a patient is achieved, the imaging quality and the diagnosis accuracy are improved, and the advantage of high scanning efficiency is achieved.

An image acquisition device (1A) is provided with a measurement unit (10) and a processing unit (20). For each coincidence counting event, that is, an event in which a pair of gamma-ray photons generated by an electron-positron pair annihilation event in a positron emission nuclide (81) is counted simultaneously by a first detector (11) and a second detector (12), a processing unit (20) has gamma-ray photons arriving at the second detector (12) after Compton scattering occurs within a subject (90). When the signal output by the first detector (11) and the signal output by the second detector (12) are lower than a first threshold value lower than 511 keV, the position of the positron emission nuclide (81) is detected selectively on the basis of the detection position and the detection time of the gamma ray photons and the position of the positron emission nuclide (81), respectively, detected by the first detector (11) and the second detector (12), and the position of the positron emission nuclide (81) is lower than a first threshold value lower than 511 keV. The position at which Compton scattering occurs in the subject (90) of the gamma ray photons is determined. This realizes an image acquisition device and an image acquisition method that can acquire a tomographic image representing anatomical information of a subject without performing image reconstruction processing.

This invention relates to a cyclic polypeptide molecular probe targeting neurocilia protein-1 (NRP-1), its preparation method, and its applications. The cyclic polypeptide molecular probe comprises the structure shown in Formula I or Formula II, where R1 is the structure shown in Formula III or Formula IV; and R2 is a radiolabeled nuclide or a radiolabeled nuclide including a bifunctional chelating group. The technical solution of this invention exhibits excellent targeting specificity and high sensitivity for NRP-1 protein, enabling visualization of NRP-1-highly expressing tumors (such as fibrosarcoma, lung cancer, pancreatic cancer, or breast cancer) and NRP-1-positive lesions (such as metabolic diseases, sclerotic lesions, or autoimmune diseases) on positron emission tomography (PET). It shows great promise in the early diagnosis of NRP-1-highly expressing malignant tumors and in guiding clinical NRP-1 monoclonal antibody treatment regimens.

A method for determining a convolution kernel for an iterative statistical algorithm based on a continuous-to-continuous data model for image reconstruction from radiation measurements obtained in emission tomography, specifically in a Positron Emission Tomography (PET) scanner. The method improves the resolution of reconstructed images, reduces the radiation dose absorbed by patients during PET examinations, and / or shortens the measurement acquisition time without significant loss in the quality of the diagnostic images obtained. Specifically, the quality of the functional images remains at the same level. These improvements are achieved through the design of the convolution kernel, which takes into account the statistical properties of the measurement signals registered during the acquisition process in the PET scanner.

This invention provides a dose prediction system, dose prediction method, and dose prediction program for accurately evaluating particle beam irradiation doses and supporting treatment using particle beams. [Solution] The support device 20 comprises an irradiation device 31 that irradiates with a particle beam, a detection device 32 that measures the irradiation area of ​​the particle beam, an imaging device 33 that photographs the light emission of the irradiation area, and a control unit 21 that predicts the irradiation dose by the irradiation device 31. The control unit 21 acquires the light emission distribution of the surface of the irradiated object irradiated with the particle beam, acquires the activity distribution of positron emission nuclei generated on the side surface of the irradiated object, and calculates a three-dimensional dose distribution using the light emission distribution and the activity distribution.

Systems and methods for estimating mean randomness include: acquiring list pattern data describing true and delayed coincidences detected by a positron emission tomography (PET) scanner during a scan of an object; determining, based on the list pattern data, delayed coincidences including said crystals for each crystal of the PET scanner and for each of a plurality of time periods of the scan; for each crystal, determining a single event rate associated with each time period based on the delayed coincidences determined for the crystal within the time period; for each time period, determining an estimated mean randomness for each of a plurality of crystal pairs based on the single event rate associated with the time period for each crystal of the crystal pair; and reconstructing an image of the object based on the estimated mean randomness for each time period and the detected true coincidences.

A PET imaging system includes a gantry having a patient tunnel, and a first detector unit and a second detector unit housed inside the gantry, each detector unit including a plurality of detector elements in a helical arrangement about an axial axis of the imaging system. Each of the detector elements in the second detector unit is spaced apart from a corresponding detector element in the first detector unit by an axial gap. Each detector element has an axial position. Each of the first and second detector units has its detector elements arranged such that the set of detector elements is positioned such that each detector element in the set is offset from an adjacent detector element in the detector unit, such that a maximum difference between the axial positions of the detector elements in each detector unit is less than or equal to the axial gap.

Disclosed herein are methods and apparatus for acquiring positron emission (or PET) data in the presence of ionizing radiation that causes PET detector afterglow. In one variation, the method includes adjusting a coincidence trigger threshold of a PET detector during a treatment procedure. In one variation, the method includes adjusting a gain factor (e.g., a gain factor for multiplying and / or shifting output (s) of PET detector (s)) used in positron emission data acquisition during a treatment procedure. In some variations, a method for acquiring positron emission data during a radiotherapy procedure includes suspending communication between a PET detector and a signal processor of a controller for a predetermined period of time after emission of a radiation pulse by a linear accelerator.

The present invention addresses the problem of providing a compound that can be used as a tracer that can detect the infiltration of lymphocytes into cardiac muscle tissue by means of positron emission tomography (PET) or the like. A compound labeled with radiopositron emission nuclide C11 ([11C]) represented by general formula (I) or a pharmaceutically acceptable salt thereof (in the formula, R1 is a chlorine atom, m is an integer of 1-3, at least one of R2, R3, R4, R5, R6, and R7 is a linear or branched C1-6 alkyl group having a radiopositron emission nuclide C11 [11C], and other than a hydrogen atom, and R1 is a hydrogen atom, and R2 is an integer of 1-3, or a pharmaceutically acceptable salt of the compound labeled with the radiopositron emission nuclide C11 [11C], or a pharmaceutically acceptable salt of the compound labeled with the radiopositron emission nuclide C11 [11C]. And R8 represents a hydrogen atom or a linear or branched alkyl group having 1-6 carbon atoms).

The application discloses a portable positron emission imaging device and an imaging system. The portable positron emission imaging device can include: a pair of support structures pivotably installed; a pair of detectors mechanically fixed to the pair of support structures, respectively; and a readout circuit module, wherein the pair of detectors are electrically connected to the readout circuit module, wherein the pair of support structures are configured to be able to pivot between a first pivot position and a second pivot position, in the first pivot position, the pair of detectors surround a first detection part of an object to be detected, in the second pivot position, the pair of detectors surround a second detection part of the object to be detected. The portable positron emission imaging device and the imaging system can effectively expand the application range of the PET device or system.

Provided is a signal processing device capable of calculating the detection time at which radiation is detected by a radiation detection device in consideration of the characteristics of the radiation detection device. A signal processing device (3) processes an output signal from a radiation detection device (2) including a plurality of scintillators that emit fluorescence in response to incident radiation and a plurality of light-receiving elements that detect the fluorescence, and is provided with a processor that performs: a determination process in which the radiation detection device (2) detects the fluorescence on the basis of the output signal; determining the detection time when the light receiving element detects the fluorescence emitted by the scintillator and the energized amount endowed by the light receiving element; and a calculation process for calculating, as a detection time for fluorescence detection by the radiation detection device, a weighted average value of the detection time at which each light-receiving element has detected, the weighted average value having, as a weight, the n power (n is a real number greater than 1) of the energy corresponding to each light-receiving element.

The invention concerns a combined magnetic resonance imaging and positron emission tomography apparatus (1) comprising: a magnetic resonance imaging machine (2), adapted to provide a total-body anatomical image of a patient undergoing diagnostic testing; a positron emission tomography machine (3), adapted to provide a total-body metabolic image of said patient undergoing diagnostic testing; at least one sliding table (4), adapted to accommodate the patient undergoing diagnostic testing by means of said machines (2, 3); a control console (5), operatively associated with said machines (2, 3) and with said sliding table (4), wherein the machines (2, 3) are configured to cooperate reciprocally to generate total-body diagnostic images obtained with the acquisition, reconstruction and analysis of PET metabolic images integrated with MRI attenuation maps, thus allowing total-body MRI-PET diagnostic images to be obtained deriving from the superimposition of metabolic and anatomical images of the patient under examination.

The present application relates to the technical field of brain disease determination, in particular to an image classification method, device and equipment and storage medium. Magnetic resonance images can accurately reflect the changes in brain structure caused by lesions, and positron emission tomography images can accurately reflect the changes in brain function caused by lesions. The present application first uses a large kernel attention (LKA) module to learn an attention map. Then, advanced feature learning is performed through a backbone network composed of a CNN and a Transformer dual branch. The present application also designs a modal feature fusion block (MFFB) to interactively fuse MRI and PET features in the backbone network. Finally, after extracting the advanced features, a spatial channel attention module (SCA) is used to process the obtained advanced features in space and channels. A large number of experimental results on the ADNI dataset show that the model of the present application is superior to the most advanced method, indicating the effectiveness of the method proposed by the present application.

Disclosed is a compound represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof. The variables of structural formula (I) are described herein. The compound of the inventon can be attached to chelating groups for radionuclide binding and are therefore suitable for radioimaging and / or radiotherapy applications, for example the disclosed compounds can be radiolabeled with a positron emitter such as 18P, 68Ga or MCu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 225 Ac, a beta particle emitter such as 67Cu or 177Lu, or an Auger electron emitter (e.g. niIn, 67Ga, "mTc, 195mPt, 125I and 1231). The compounds can also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to tumors, for example conjugated to gemcitabine or doxycycline, or a venom. Likewise, the compounds can be conjugated to compounds having physiological effects, such as TLR agonists to stimulate the immune response of a recipient.

A system and method including: localization of a first frame of positron emission tomography data acquired by an imaging device to a first frame of Cartesian data; generation of a first Cartesian image volume based on the first frame of Cartesian data; display of the first Cartesian image volume; localization of a second frame of positron emission tomography data acquired by the imaging device to a second frame of Cartesian data; generation of a second Cartesian image volume based on the second frame of Cartesian data; and display of the combined Cartesian image volumes.

A dual-ended readout positron emission tomography (PET) detector, a method for determining photon information, and a PET imaging device are provided. The dual-ended readout PET detector includes a crystal array, a first processing unit, and a second processing unit. The crystal array includes a plurality of crystal units. The first processing unit is disposed at a first end of the crystal array. The second processing unit is disposed at a second end of the crystal array, and the first end and the second end are disposed opposite to each other. Each of the plurality of crystal units includes a side surface between the first end and the second end, and the side surfaces of at least two of the plurality of crystal units have different optical conductivities.

According to various aspects of this disclosure, the present disclosure relates to an automated process for the radiosynthesis of [18F]FSPG, a positron emission tracer. The automated optimized process of the present invention enables the centralized and large-scale production of [18F]FSPG for commercial use.

The invention relates to an epilepsy minimally invasive surgery target spot determining method and device based on a nerve image fingerprint, electronic equipment and a storage medium, the method comprises the steps that a first image reflecting the brain of a patient is acquired, the first image comprises a diseased side image representing the diseased side brain and a normal side image representing the normal side brain, and the first image is used for representing the diseased side brain; the first image is positron emission type computed tomography; determining a voxel value difference between the diseased side image and the normal side image; and determining at least one first to-be-damaged area based on the plurality of voxel value differences and a difference threshold. Compared with other brain metabolism, the method disclosed by the invention has the advantage that individual differences do not exist in the comparison process. And objectively determining the potential position of the surgical target based on the voxel value difference and the difference threshold. The reference basis of the operation target position is provided for a doctor, the accuracy of determining the target position is improved, and the prognosis of a patient is improved.

The invention discloses a compound represented by the following structural formula (I). Or a pharmaceutically acceptable salt thereof. The variables of Structural Formula (I) are described herein. The compounds of the invention can be attached to chelating groups for radionuclide binding, and thus are suitable for radioimaging and / or radiotherapy applications, for example, the disclosed compounds can be radiolabeled with positron emitters such as 18F, 68Ga or 64Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 225 Ac, a beta particle emitter such as 67 Cu or 177 Lu or Auger electron emitters (e.g., 111 In, 67 Ga, 99 mTc, 195 mPt, 125 I, and 123 I). The compounds may also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to a tumor, such as conjugated to gemcitabine or doxycycline or venom. Likewise, the compound may be conjugated to a compound having a physiological action, such as a TLR agonist, to stimulate the immune response of the receptor.

Systems and methods are disclosed for automatically performing motion correction in dynamic positron emission tomography scans, such as dynamic positron emission tomography myocardial perfusion imaging studies. An automated algorithm can be used. The algorithm can use simplex iterative optimization of a count-based cost-function customized to different dynamic phases for performing frame-by-frame motion correction.

Positron emission tomography (PET) is a bioimaging technique that relies on positron emitting probes. PET probes can be obtained from a non-labeled probe by a late-stage radiolabelling step with a radionuclide, prior to the injection of the probe to the patient. Because of the short half-life duration of most radionuclides, the radiolabelling step must be rapid. The present invention provides a method allowing the rapid embedding of 68Ga into particles comprising polydopamine. The particles labeled with the method are very stable and are obtained in high yield with a high purity. It has been shown that radiolabeled particles obtained with the method of the invention and functionalized with antibodies were efficient in revealing lung and kidney inflammation via a whole-body PET scan in a LPS-induced sepsis mouse model. Such probes, when they further incorporate magnetic nanoparticles, carry a high potential to improve the diagnosis of inflammation via PET-MRI.